Spatially patterned kidney assembloids recapitulate progenitor self-assembly and enable high-fidelity in vivo disease modeling
- PMID: 40967224
- DOI: 10.1016/j.stem.2025.08.013
Spatially patterned kidney assembloids recapitulate progenitor self-assembly and enable high-fidelity in vivo disease modeling
Abstract
Current kidney organoids do not recapitulate the kidney's complex spatial patterning and function, limiting their applications. The human kidney comprises one million nephrons, derived from nephron progenitor cells, that connect to an arborized ureteric progenitor cell-derived collecting system. Here, we develop spatially organized mouse and human kidney progenitor assembloid (KPA) models in which the nephrons undergo extensive development and fuse to a centrally located collecting system, recapitulating kidney progenitor self-assembly processes observed in vivo. KPAs show dramatically improved cellular complexity and maturity and exhibit several aspects of major kidney functions in vitro and in vivo. Modeling human autosomal dominant polycystic kidney disease (ADPKD) with genome-edited, in vivo-grown human KPAs recapitulated the cystic phenotype and the molecular and cellular hallmarks of the disease and highlighted the crosstalk among cyst epithelium, stroma, and macrophages. The KPA platform opens new avenues for high-fidelity disease modeling and lays a strong foundation for kidney regenerative medicine.
Keywords: collecting duct; functional maturation; kidney organoid; nephron; nephron patterning; nephron progenitor cell; pluripotent stem cell; polycystic kidney disease; progenitor plasticity; ureteric progenitor cell.
Copyright © 2025 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests A.P.M. is a scientific advisor or consultant for eGENESIS, Trestle Biotherapeutics, GentiBio, and IVIVA Medical. J.P.-P. and G.G. are co-founders of Macula Densa Cell LLC, a biotechnology company that develops therapeutics to target macula densa cells for a regenerative treatment for chronic kidney disease. Macula Densa Cell LLC has a patent entitled “Targeting macula densa cells as a new therapeutic approach for kidney disease” (US patents 10,828,374 and 11,318,209). Z. Li, B.H., P.M., Z.Z., and A.P.M. have applied for intellectual property protection on technologies discussed here.
MeSH terms
LinkOut - more resources
- Full Text Sources
- Medical
- Molecular Biology Databases
 
        